Claims for Patent: 9,511,109

Summary for Patent: 9,511,109

Title:	Combination therapy with peptide epoxyketones
Abstract:	The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
Inventor(s):	Kirk; Christopher J. (Millbrae, CA), Demo; Susan D. (San Francisco, CA), Bennett; Mark K. (Moraga Town, CA)
Assignee:	Onyx Therapeutics, Inc. (Thousand Oaks, CA)
Application Number:	14/470,224
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,511,109
Patent Claims:	1. A method for treating cancer, comprising administering to a patient, in combination, (1) a peptide epoxyketone proteasome inhibitor, or a pharmaceutically acceptable salt thereof; and (2) a therapeutic agent; wherein the peptide epoxyketone proteasome inhibitor has the following structure: ##STR00024## the therapeutic agent comprises lenalidomide and dexamethasone; the cancer is multiple myeloma; and the efficacy shown by administering (1) and (2) in combination is greater than the efficacy shown by administering either of (1) or (2) alone. 2. The method of claim 1, wherein the peptide epoxyketone proteasome inhibitor and the therapeutic agent are administered within about 5 minutes to within about 48 hours of one another. 3. A method for treating cancer, consisting essentially of administering to a patient, in combination, (1) a peptide epoxyketone proteasome inhibitor, or a pharmaceutically acceptable salt thereof; (2) lenalidomide, and (3) dexamethasone; wherein the peptide epoxyketone proteasome inhibitor has the following structure: ##STR00025## the cancer is multiple myeloma; and the efficacy shown by administering (1) and (2) in combination is greater than the efficacy shown by administering either of (1) or (2) alone. 4. The method of claim 3 wherein the peptide epoxyketone proteasome inhibitor and lenalidomide are administered within about 5 minutes to within about 48 hours of one another. 5. The method or claim 4 wherein the peptide epoxyketone proteasome inhibitor, lenalidomide and dexamethasone are administered within about 5 minutes to within about 48 hours of one another.